State Street’s Impact BioMedical IBO Stock Holding History
Bought
Maintained
Sold
Other funds holding IBO
State Street's IBO Position: Q3 2026 in Review
State Street increased its Impact BioMedical (IBO) stake by 1.1% in Q3 2026, buying an estimated $3.17K and bringing the position to 48,711 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #3817.
State Street first reported a position in IBO in Q4 2024 and has held it in 8 quarters since. The position peaked at $365K in Q1 2026. 19 funds tracked by Wall St. Rank hold IBO as of Q3 2026.
- State Street held 48,711 shares of Impact BioMedical worth $273K as of Q3 2026.
- State Street bought 542 Impact BioMedical shares in Q3 2026, an estimated $3.17K.
- Impact BioMedical made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3817 holding.
- State Street first reported a position in Impact BioMedical in Q4 2024 and has held it in 8 quarters since.
- State Street's Impact BioMedical position peaked at $365K in Q1 2026.
- 19 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2026.
Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.